Sandra Codony
Overview
Explore the profile of Sandra Codony including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jarne-Ferrer J, Sanchez J, Codony S, Schneider M, Muller C, Sanfeliu C, et al.
ACS Pharmacol Transl Sci
. 2025 Feb;
8(2):533-542.
PMID: 39974649
Neuroinflammation is widely recognized as a key pathological hallmark of Alzheimer's disease (AD). Recently, inhibiting soluble epoxide hydrolase (sEH) has emerged as a promising therapeutic strategy for AD. sEH plays...
2.
Grinan-Ferre C, Jarne-Ferrer J, Bellver-Sanchis A, Codony S, Puigoriol-Illamola D, Sanfeliu C, et al.
CNS Neurosci Ther
. 2023 Oct;
30(4):e14511.
PMID: 37905690
Background: Neuroinflammation is widely recognized as a significant hallmark of Alzheimer's disease (AD). To combat neuroinflammation, the inhibition of the soluble epoxide hydrolase (sEH) enzyme has been demonstrated crucial. Importantly,...
3.
Codony S, Entrena J, Calvo-Tusell C, Jora B, Gonzalez-Cano R, Osuna S, et al.
J Med Chem
. 2022 Oct;
65(20):13660-13680.
PMID: 36222708
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based...
4.
Codony S, Pont C, Grinan-Ferre C, Di Pede-Mattatelli A, Calvo-Tusell C, Feixas F, et al.
J Med Chem
. 2022 Mar;
65(6):4909-4925.
PMID: 35271276
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, such as Alzheimer's disease (AD), which remains inefficiently treated, the advent of multitarget drug discovery has brought a new...
5.
Martin-Lopez J, Codony S, Bartra C, Morisseau C, Loza M, Sanfeliu C, et al.
Pharmaceuticals (Basel)
. 2021 Dec;
14(12).
PMID: 34959721
The pharmacological inhibition of soluble epoxide hydrolase (sEH) has been suggested as a potential therapy for the treatment of pain and inflammatory diseases through the stabilization of endogenous epoxyeicosatrienoic acids....
6.
Codony S, Calvo-Tusell C, Valverde E, Osuna S, Morisseau C, Loza M, et al.
J Med Chem
. 2021 May;
64(9):5429-5446.
PMID: 33945278
The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as...
7.
Grinan-Ferre C, Companys-Alemany J, Jarne-Ferrer J, Codony S, Gonzalez-Castillo C, Ortuno-Sahagun D, et al.
Int J Mol Sci
. 2021 Apr;
22(7).
PMID: 33810307
Niemann-Pick type C (NPC) disease is a rare autosomal recessive inherited childhood neurodegenerative disease characterized by the accumulation of cholesterol and glycosphingolipids, involving the autophagy-lysosome system. Inhibition of soluble epoxide...
8.
Codony S, Pujol E, Pizarro J, Feixas F, Valverde E, Loza M, et al.
J Med Chem
. 2020 Aug;
63(17):9237-9257.
PMID: 32787085
pharmacological inhibition of soluble epoxide hydrolase (sEH) reduces inflammatory diseases, including acute pancreatitis (AP). Adamantyl ureas are very potent sEH inhibitors, but the lipophilicity and metabolism of the adamantane group...
9.
Grinan-Ferre C, Codony S, Pujol E, Yang J, Leiva R, Escolano C, et al.
Neurotherapeutics
. 2020 Jun;
17(4):1825-1835.
PMID: 32488482
The inhibition of the enzyme soluble epoxide hydrolase (sEH) has demonstrated clinical therapeutic effects in several peripheral inflammatory-related diseases, with 3 compounds in clinical trials. However, the role of this...
10.
Codony S, Valverde E, Leiva R, Brea J, Loza M, Morisseau C, et al.
Bioorg Med Chem
. 2019 Sep;
27(20):115078.
PMID: 31488357
Soluble epoxide hydrolase (sEH) inhibitors are potential drugs for several diseases. Adamantyl ureas are excellent sEH inhibitors but have limited metabolic stability. Herein, we report the effect of replacing the...